Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice

Pharmacogenomics

Volumn 16, Issue 18, 2015, Pages 2007-2018

  Schackman, Bruce R ^a   Haas, David W ^b   Park, Sanghee S ^c   Li, X Cynthia ^c   Freedberg, Kenneth A ^c,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

antiretroviral therapy; cost effectiveness; dose optimization; genotyping; HIV

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GENERIC DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; ENZYMOLOGY; GENETICS; GENOTYPE; HIV INFECTIONS; THEORETICAL MODEL;

ANTI-HIV AGENTS; BENZOXAZINES; COST-BENEFIT ANALYSIS; CYTOCHROME P-450 CYP2B6; GENOTYPE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS;

EID: 84948988283     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.142     Document Type: Article

References (52)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2015). https://aidsinfo.nih.gov/contentfiles/lvguidelines
2. Gulick RM, Ribaudo HJ, Shikuma CM et al. Three-vs fourdrug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296(7), 769-781 (2006).
3. Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann. Intern. Med. 154(7), 445-456 (2011).
4. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18(18), 2391-2400 (2004).
5. Rotger M, Colombo S, Furrer H et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15(1), 1-5 (2005).
6. Haas DW, Smeaton LM, Shafer RW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J. Infect. Dis. 192(11), 1931-1942 (2005).
7. Holzinger ER, Grady B, Ritchie MD et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet. Genomics 22(12), 858-867 (2012).
8. Wang J, Sonnerborg A, Rane A et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16(3), 191-198 (2006).
9. Ribaudo HJ, Liu H, Schwab M et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J. Infect. Dis. 202(5), 717-722 (2010).
10. Gatanaga H, Hayashida T, Tsuchiya K et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6∗6 and 26. Clin. Infect. Dis. 45(9), 1230-1237 (2007).
11. Encore Study Group, Puls R, Amin J et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 383(9927), 1474-1482 (2014).
12. Encore1 Study Group. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, noninferiority ENCORE1 study. Lancet Infect. Dis. 15(7), 793-802 (2015).
13. Haas DW, Severe P, Jean Juste MA, Pape JW, Fitzgerald DW. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti. J. Antimicrob. Chemother. 69(8), 2187-2190 (2014).
14. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15(1), 71-75 (2001).
15. Gallego L, Barreiro P, Del Rio R et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin. Infect. Dis. 38(3), 430-432 (2004).
16. Clifford DB, Evans S, Yang Y et al. Impact of efavirenz on neuropsychological performance and symptoms in HIVinfected individuals. Ann. Intern. Med. 143(10), 714-721 (2005).
17. Gutierrez F, Navarro A, Padilla S et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin. Infect. Dis. 41(11), 1648-1653 (2005).
18. Read TR, Carey D, Mallon P et al. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. AIDS 23(16), 2222-2223 (2009).
19. Takahashi M, Ibe S, Kudaka Y et al. No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART. AIDS Res. Hum. Retroviruses 23(8), 983-987 (2007).
20. Martin AS, Gomez AI, Garcia-Berrocal B et al. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Pharmacogenomics 15(7), 997-1006 (2014).
21. Morris BL, Scott CA, Wilkin TJ et al. Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin. Trials 13(1), 1-10 (2012).
22. Walensky RP, Sax PE, Nakamura YM et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann. Intern. Med. 158(2), 84-92 (2013).
23. Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S. (2014). http://news.bms.com/press-release/bristol-myers-squibb
24. Gold MR, Siegel JE, Einstein MC. Cost-effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
25. Braithwaite RS, Goulet J, Kudel I, Tsevat J, Justice AC. Quantifying the decrement in utility from perceived side effects of combination antiretroviral therapies in patients with HIV. Value Health 11(5), 975-979 (2008).
26. Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 115(17), 3858-3867 (2009).
27. Freedberg KA, Losina E, Weinstein MC et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 344(11), 824-831 (2001).
28. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B∗5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22(15), 2025-2033 (2008).
29. Schackman BR, Fleishman JA, Su AE et al. The lifetime medical cost savings from preventing HIV in the United States. Med. Care 53(4), 293-301 (2015).
30. Mellors JW, Munõz A, Giorgi JV et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126(12), 946-954 (1997).
31. Freedberg KA, Scharfstein JA, Seage GR III The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 279(2), 130-136 (1998).
32. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (2013). https://aidsinfo.nih.gov/contentfiles/lvguidelines
33. Losina E, Schackman BR, Sadownik SN et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin. Infect. Dis. 49(10), 1570-1578 (2009).
34. Ross EL, Weinstein MC, Schackman BR et al. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin. Infect. Dis. 60(7), 1102-1110 (2015).
35. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE 7(2), e31591 (2012).
36. Pozniak AL, Gallant JE, Dejesus E et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J. Acquir. Immune Defic. Syndr. 43(5), 535-540 (2006).
37. Sax PE, Dejesus E, Mills A et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3 trial, analysis of results after 48 weeks. Lancet 379(9835), 2439-2448 (2012).
38. Thomson Corporation. Red Book: Pharmacy's Fundamental Reference. Thomson PDR, NJ, USA (2014).
39. Althoff KN, Gange SJ, Klein MB et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin. Infect. Dis. 50(11), 1512-1520 (2010).
40. Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best BM. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J. Manag. Care Pharm. 17(3), 213-223 (2011).
41. Messou E, Chaix ML, Gabillard D et al. Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa. J. Acquir. Immune Defic. Syndr. 64(2), 211-219 (2013).
42. HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J. Acquir. Immune Defic. Syndr. 30(1), 21-26 (2002).
43. Schackman BR, Haas DW, Becker JE et al. Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir. Ther. 18(3), 399-408 (2013).
44. Scourfield A, Zheng J, Chinthapalli S et al. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS 26(11), 1399-1401 (2012).
45. Medicare Physician Fee Schedule (2013). www.cms.gov/apps/physician-fee-schedule/overview.aspx
46. Lubomirov R, Colombo S, Di Iulio J et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J. Infect. Dis. 203(2), 246-257 (2011).
47. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J. Infect. Dis. 201(6), 803-813 (2010).
48. Van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363(9417), 1253-1263 (2004).
49. Di Iulio J, Fayet A, Arab-Alameddine M et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19(4), 300-309 (2009).
50. Haas DW, Kwara A, Richardson DM et al. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J. Antimicrob. Chemother. 69(8), 2175-2182 (2014).
51. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. CYP2B6 (c.516G->T) and CYP2A6 (∗9B and/or∗17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br. J. Clin. Pharmacol. 67(4), 427-436 (2009).
52. Nachega JB, Parienti JJ, Uthman OA et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin. Infect. Dis. 58(9), 1297-1307 (2014).